Position of the Transparency Council – Remsima (infliximab)

At its meeting on 24 February 2025, the Transparency Council adopted position No. 23/2025 on the evaluation of the drug Remsima (infliximab) under the drug program B.33. “Treatment of patients with active rheumatoid arthritis and juvenile idiopathic arthritis (ICD-10: M05, M06, M08)”

Publication of the position >>